PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Colivelin — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Colivelin is a hybrid peptide made by fusing activity-dependent neurotrophic factor (ADNF) to a potent humanin derivative; it blocked neuronal death caused by Alzheimer's-related genes and amyloid-beta at 100 femtomolar in cell studies. · pmid:16267233

Mechanism

Given intranasally to mouse models of Alzheimer's disease, colivelin reached the brain through the olfactory bulb and lessened memory impairment, with increased STAT3 phosphorylation in the septohippocampal region. · pmid:17928813

Identity

PubChem CID 90477169: Colivelin, C119H206N32O35, 2645.1 g/mol. · pubchem:90477169

CAS registry number 867021-83-8. · pubchem:90477169

Where the evidence actually sits

Preclinical only100%

Proportion of the 2 claims about Colivelin standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. (2005) · preclinicalNasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. (2008) · preclinical20052008

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Colivelin yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work
    • Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. · pmid 16267233 · 2005
    • Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. · pmid 17928813 · 2008

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.